Daiichi Sankyo's European division has signed a partnership with German digital health company GAIA to sell a digital ...

This week's round-up of pharma licensing deals features alliances involving Tenaya Therapeutics, Sino Bio, Antengene, and A2A ...

Roche licensed petrelintide from Zealand last year for a hefty $1.4 billion upfront payment, adding it to a portfolio of half a dozen clinical-stage candidates, including dual GIP/GLP-1 agonist CT-388 ...

So, on the strength of that trial, Blackman and Grant paid $1 million (plus $10 million in Day One stock) to Takeda and $2 ...

France's Servier has emerged as the suitor, with an all-cash offer to buy Day One and its fast-growing brain cancer therapy Ojemda (tovorafenib) for $21.50 per share, valuing the California company at ...

Chakravarthi AVPS, Chairman of the Federation of Pharma Entrepreneurs, provides an overview of global strategies to accelerate access to innovative therapies, bridging equity, regulation, and ...

The FDA has started a review of Hansa Biopharma's imlifidase for patients who need a kidney transplant, but for whom finding ...

Cardiff, Wales-based Antiverse's computational platform has been set up to find antibodies against challenging drug targets, ...

Pfizer has claimed its first regulatory approval for a GLP-1 agonist in obesity, getting a green light in China for ecnoglutide, a once-weekly injectable drug licensed from Hangzhou-based Sciwind ...

Italy's AI Law establishes new criminal offenses, creating meaningful risks for US executives and employees. The law ...

Shares in PepGen were down more than 21% after the FDA placed a partial clinical hold on its lead drug PGN-EDODM1, for rare ...

Arbutus and Genevant's complaint claimed that Moderna's mRNA-based Spikevax shot used lipid nanoparticle (LNP) delivery ...